カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

カスタム抗体の世界市場予測（～2028）：サービス別、種類別、ソース別、用途別、疾患別、エンドユーザー別

■ 英語タイトル：Custom Antibody Market by Service (Development, Purification, Labelling), Type (Monoclonal, Recombinant), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology), End User (Biopharma, CROs) - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：BT6817-23）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：BT6817-23
■ 発行日：2023年2月28日
■ 調査対象地域：グローバル
■ 産業分野：バイオテクノロジー
■ ページ数：278
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[カスタム抗体の世界市場予測（～2028）：サービス別、種類別、ソース別、用途別、疾患別、エンドユーザー別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

MarketsandMarkets社によると、世界のカスタム抗体市場規模が2023年548百万ドルから2028年860百万ドルに達し、予測期間中に年平均9.4％で成長すると予測されています。本調査レポートでは、カスタム抗体の世界市場を広く調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、サービス別（抗体開発、抗体産生＆精製、抗体断片化＆標識）分析、種類別（モノクローナル抗体、ポリクローナル抗体、組み換え抗体、その他）分析、ソース別（マウス、ウサギ、その他）分析、用途別（研究、治療）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報などについて以下の構成でまとめています。また、本書には、Thermo Fisher Scientific (US)、GenScript (China)、Abcam plc. (UK)、Cell Signaling Technology, Inc (US)、Bio-Rad Laboratories, Inc (US)、Merck KGaA (Germany)、Agilent Technologies, Inc (Germany)、PerkinElmer, Inc (US)、Rockland Immunochemicals, Inc (US)、ProMab Biotechnologies, Inc (US)、Innovagen AB (Sweden)などの企業情報が含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のカスタム抗体市場規模：サービス別
- 抗体開発サービスの市場規模
- 抗体産生＆精製サービスの市場規模
- 抗体断片化＆標識サービスの市場規模
・世界のカスタム抗体市場規模：種類別
- モノクローナル抗体の市場規模
- ポリクローナル抗体の市場規模
- 組み換え抗体の市場規模
- その他種類の市場規模
・世界のカスタム抗体市場規模：ソース別
- マウス由来のカスタム抗体市場規模
- ウサギ由来のカスタム抗体市場規模
- その他ソースの市場規模
・世界のカスタム抗体市場規模：用途別
- 研究における市場規模
- 治療における市場規模
・世界のカスタム抗体市場規模：地域別
- 北米のカスタム抗体市場規模
- ヨーロッパのカスタム抗体市場規模
- アジア太平洋のカスタム抗体市場規模
- 中南米のカスタム抗体市場規模
- 中東・アフリカのカスタム抗体市場規模
・競争状況
・企業情報

“世界のカスタム抗体市場規模は2023年の5億4,800万米ドルから2028年には8億6,000万米ドルに達すると予測され、予測期間中のCAGRは9.4%”
ADC開発のための投資の増加、構造ベースの薬剤設計とカスタム抗体の治療薬mAbsの研究の高まりなどの要因が、市場の成長を加速させています。

“遺伝子組換え抗体セグメントは2023-2028年の予測期間中に最も高いCAGRで成長”
カスタム抗体市場はタイプ別に、モノクローナル抗体、ポリクローナル抗体、組み換え抗体、その他に区分されます。予測期間中、最も高いCAGRで成長すると予測されるのは組み換え抗体分野です。この成長は、組換え抗体が提供する免疫原性の低さと研究の再現性の向上によるものです。このことは、同分野の成長に好影響を与えると考えられます。

“マウス由来が2023年に圧倒的シェアを占める見込み”
ソースに基づき、市場はマウス、ウサギ、その他に区分されます。マウスは従来から研究目的のmAbs産生に好まれてきた宿主であることから、予測期間中、マウスセグメントはより速いペースで成長する見込みです。

“2022年、研究用途セグメントが圧倒的シェアを保持”
用途に基づき、カスタム抗体市場は研究用途と治療用途に区分されます。カスタム抗体市場では、研究用途分野が圧倒的なシェアを獲得します。研究および創薬開発におけるカスタム抗体の採用は、市場成長を予測する主な要因の1つです。

“がん分野は2023-2028年の予測期間中に最も高いCAGRで成長すると予想”
適応症に基づき、カスタム抗体市場は腫瘍学、感染症、免疫学、神経生物学、心血管疾患、その他に区分されます。2022年のカスタム抗体市場では、がん領域の適応症セグメントが圧倒的なシェアを占めています。がん治療におけるmAbsとカスタム抗体の使用拡大が、市場成長を予測する主な要因の1つです。

“アジア太平洋地域はより速いペースで成長”
カスタム抗体市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに分けられます。2022年には、北米がカスタム抗体市場で圧倒的なシェアを占めました。同地域の優位性は、同地域の有力かつ主要な市場プレイヤーの存在や、カスタム抗体の継続的な研究活動など、さまざまな要因によるものです。アジア太平洋地域は、個別化治療薬に対する意識の高まり、同地域における抗体開発のための政府による研究イニシアチブの高まり、カスタム抗体市場における新規参入企業の出現など、さまざまな要因により、より速いペースで成長する可能性があります。
本レポートのために実施した一次インタビューは以下のように分類できます：

– 回答者別 供給側60％、需要側40％
– 回答者の役職別（供給側） 管理職-45%、CXOおよび取締役-25%、経営幹部-15%、その他-15.0％
– 地域別 北米 -40%、欧州 -25%、アジア太平洋地域 -20%、中南米 -10%、中東・アフリカ -5％

レポート掲載企業リスト
• Thermo Fisher Scientific (US)
• GenScript (China)
• Abcam plc. (UK)
• Cell Signaling Technology, Inc (US)
• Bio-Rad Laboratories, Inc (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc (Germany)
• PerkinElmer, Inc (US)
• Rockland Immunochemicals, Inc (US)
• ProMab Biotechnologies, Inc (US)
• Innovagen AB (Sweden)
• OriGene Technologies (US)
• Bio-Techne (US)
• Creative Diagnostics (US)
• Sino Biological, Inc (China)
• RayBiotech Life, Inc (US)
• Abbiotec, Inc (US)
• ProSci (US)
• Boster Biological Technology (US)
• CUSABIO Technology LLC (US)
• Biointron (China)
• Kaneka Eurogentech S.A. (Belgium)
• Creative Biolabs (US)
• Envigo (US)
• Imgenex India Pvt. Ltd (India).

調査範囲
この調査レポートは、カスタム抗体市場の詳細な状況を掲載しています。サービス、タイプ、ソース、アプリケーション、適応症、エンドユーザー、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、カスタム抗体市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競合状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートにより、関係者は市場動向を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を得ることができます。

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 30
1.7.1 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH APPROACH 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 33
2.1.2 PRIMARY DATA 33
FIGURE 2 CUSTOM ANTIBODY MARKET: PRIMARY RESPONDENTS 34
2.2 MARKET ESTIMATION METHODOLOGY 34
2.2.1 AVERAGE MARKET SIZE ESTIMATION (2022) 35
FIGURE 3 AVERAGE MARKET SIZE ESTIMATION (2022): CUSTOM ANTIBODY MARKET 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION METHODOLOGY 36
2.3 DATA TRIANGULATION APPROACH 37
FIGURE 5 DATA TRIANGULATION METHODOLOGY 37
2.4 GROWTH RATE ASSUMPTIONS 38
2.5 GROWTH FORECAST 38
FIGURE 6 GROWTH RATE ANALYSIS 38
2.6 RISK ASSESSMENT 39
2.7 INSIGHTS FROM PRIMARY EXPERTS 39
2.8 CUSTOM ANTIBODY MARKET: RECESSION IMPACT 40
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH) 40
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 41
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 41
3 EXECUTIVE SUMMARY 42
FIGURE 7 CUSTOM ANTIBODY MARKET, BY SERVICE, 2023 VS. 2028 42
FIGURE 8 CUSTOM ANTIBODY MARKET SHARE, BY TYPE, 2023 VS. 2028 43
FIGURE 9 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE, 2023 VS. 2028 44
FIGURE 10 CUSTOM ANTIBODY MARKET SHARE, BY APPLICATION, 2023 VS. 2028 44
FIGURE 11 CUSTOM ANTIBODY MARKET SHARE, BY INDICATION, 2023 VS. 2028 45
FIGURE 12 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023 VS. 2028 46
FIGURE 13 CUSTOM ANTIBODY MARKET: GEOGRAPHICAL SNAPSHOT 47
4 PREMIUM INSIGHTS 48
4.1 CUSTOM ANTIBODY MARKET OVERVIEW 48
FIGURE 14 RISING DEMAND FOR MONOCLONAL ANTIBODIES IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET 48
4.2 NORTH AMERICA: CUSTOM ANTIBODY MARKET SHARE, BY TYPE & COUNTRY (2022) 49
FIGURE 15 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 49
4.3 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE (2022) 49
FIGURE 16 MICE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 49
4.4 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 18 CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
TABLE 4 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS 52
5.2.1 DRIVERS 52
5.2.1.1 Rising research activities and funding investments for antibody development 52
5.2.1.2 Growing use of custom antibodies in precision medicine 53
5.2.1.3 Use of antibodies in biomarker identification and validation 53
5.2.1.4 Quality concerns over catalog antibodies 54
5.2.2 RESTRAINTS 54
5.2.2.1 High costs and complexities associated with antibody development 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Emerging markets 55
5.2.3.2 Rising therapeutic applications for mAbs 55
FIGURE 19 NUMBER OF APPROVED ANTIBODY THERAPEUTICS (2016−2022) 56
5.2.4 CHALLENGES 56
5.2.4.1 Challenges associated with immunization of host animals 56
5.2.4.2 Presence of alternative antibodies 57
5.3 VALUE CHAIN ANALYSIS 57
FIGURE 20 CUSTOM ANTIBODY MARKET: VALUE-CHAIN ANALYSIS 57
5.4 ECOSYSTEM ANALYSIS 59
FIGURE 21 CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS 59
5.4.1 ROLE IN ECOSYSTEM 59
5.5 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 5 CUSTOM ANTIBODY MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.5.1 THREAT OF NEW ENTRANTS 60
5.5.2 THREAT OF SUBSTITUTES 60
5.5.3 BARGAINING POWER OF SUPPLIERS 61
5.5.4 BARGAINING POWER OF BUYERS 61
5.5.5 DEGREE OF COMPETITION 61
5.6 PATENT ANALYSIS 62
FIGURE 22 CUSTOM ANTIBODY MARKET: PATENT ANALYSIS 62
5.7 PRICING ANALYSIS 62
5.7.1 AVERAGE SELLING PRICE TREND 62
5.7.2 INDICATIVE PRICING ANALYSIS 63
TABLE 6 SELLING PRICE OF SERVICES PROVIDED BY GENSCRIPT 63
TABLE 7 SELLING PRICE OF SERVICES PROVIDED BY ABBIOTEC, INC. 63
5.7.3 INDICATIVE PRICING ANALYSIS, BY REGION 63
TABLE 8 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR INDIA 63
TABLE 9 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR US 64
5.8 TECHNOLOGICAL ANALYSIS 64
5.8.1 CUSTOM ANTIBODY SERVICES 64
5.9 REGULATORY LANDSCAPE 65
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
5.10 KEY CONFERENCES & EVENTS IN 2023 66
TABLE 11 CUSTOM ANTIBODY MARKET: DETAILED LIST OF CONFERENCES & EVENTS 66
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 67
FIGURE 23 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS 67
FIGURE 24 CUSTOM ANTIBODY MARKET: KEY BUYING CRITERIA FOR END USERS 67
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68
FIGURE 25 REVENUE SHIFT AND NEW REVENUE 68
6 CUSTOM ANTIBODY MARKET, BY SERVICE 69
6.1 INTRODUCTION 70
TABLE 12 CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 70
6.2 ANTIBODY DEVELOPMENT 70
TABLE 13 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 71
TABLE 14 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 71
TABLE 15 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 16 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 17 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 18 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 73
6.2.1 ANTIBODY CHARACTERIZATION 73
6.2.1.1 Crucial step in research & biopharmaceutical development for elimination of antibodies to drive market 73
TABLE 19 CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 20 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 21 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 22 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 23 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.2.2 ANTIGEN PREPARATION 76
6.2.2.1 Development of research antibodies using bioinformatics tools to support market growth 76
TABLE 24 CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 25 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 26 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 28 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION 79
6.2.3.1 Rising demand for therapeutic antibodies to drive market 79
TABLE 29 CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 30 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 31 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 32 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 33 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 82
6.3 ANTIBODY PRODUCTION & PURIFICATION 82
6.3.1 RISING NEED FOR HIGH-QUALITY THERAPEUTICS TO DRIVE MARKET 82
TABLE 34 CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 35 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 36 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 37 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 38 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 85
6.4 ANTIBODY FRAGMENTATION & LABELING 85
6.4.1 RISING NEED FOR SPECIFIC ANTIBODIES IN DETECTION OF NEW BIOMOLECULES TO SUPPORT MARKET GROWTH 85
TABLE 39 CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING. BY REGION, 2021–2028 (USD MILLION) 86
TABLE 40 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 41 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 42 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 43 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021–2028 (USD MILLION) 88
7 CUSTOM ANTIBODY MARKET, BY TYPE 89
7.1 INTRODUCTION 90
TABLE 44 CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 90
7.2 MONOCLONAL ANTIBODIES 90
7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO DRIVE MARKET 90
TABLE 45 CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 46 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 47 EUROPE: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 48 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 49 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 93
7.3 POLYCLONAL ANTIBODIES 93
7.3.1 ABILITY TO BE STABLE AND WITHSTAND VARIATIONS IN TEMPERATURE TO FUEL UPTAKE 93
TABLE 50 CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY TYPE, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 51 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 52 EUROPE: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 53 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 54 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 96
7.4 RECOMBINANT ANTIBODIES 96
7.4.1 LOW IMMUNOGENICITY AND RISING RESEARCH REPRODUCIBILITY TO DRIVE MARKET 96
TABLE 55 CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 56 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 57 EUROPE: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, 2021–2028 (USD MILLION) 98
TABLE 58 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 59 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.5 OTHER CUSTOM ANTIBODIES 99
TABLE 60 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 61 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 62 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 63 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 64 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
8 CUSTOM ANTIBODY MARKET, BY SOURCE 102
8.1 INTRODUCTION 103
TABLE 65 CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 103
8.2 MICE 103
8.2.1 CONVENTIONALLY PREFERRED HOSTS FOR MAB PRODUCTION TO INCREASE UPTAKE 103
TABLE 66 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 67 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 68 EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 69 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 70 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021–2028 (USD MILLION) 105
8.3 RABBITS 105
8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET 105
TABLE 71 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 72 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 73 EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 74 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 75 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021–2028 (USD MILLION) 108
8.4 OTHER SOURCES 108
TABLE 76 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 77 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 78 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 79 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 80 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 110
9 CUSTOM ANTIBODY MARKET, BY APPLICATION 111
9.1 INTRODUCTION 112
TABLE 81 CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
9.2 RESEARCH 112
9.2.1 RISING R&D ACTIVITIES FOR MAB-BASED THERAPEUTICS TO DRIVE MARKET 112
TABLE 82 CUSTOM ANTIBODY MARKET FOR RESEARCH, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 83 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 84 EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 85 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 86 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 115
9.3 THERAPEUTICS 115
9.3.1 GROWING USE OF MABS IN TARGETED THERAPY FOR AUTOIMMUNE DISEASES TO DRIVE MARKET 115
TABLE 87 CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 88 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 89 EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 90 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 91 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 118
10 CUSTOM ANTIBODY MARKET, BY INDICATION 119
10.1 INTRODUCTION 120
TABLE 92 CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 120
10.2 ONCOLOGY 120
10.2.1 GROWING USE OF MABS IN CANCER TREATMENT TO DRIVE MARKET 120
TABLE 93 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 94 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 95 EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 96 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 97 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 123
10.3 INFECTIOUS DISEASES 123
10.3.1 WIDE USAGE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO DRIVE MARKET 123
TABLE 98 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 99 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 100 EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 101 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 102 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 125
10.4 IMMUNOLOGY 126
10.4.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES IN IMMUNOLOGY TO DRIVE MARKET 126
TABLE 103 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 104 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 105 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 106 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 107 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 128
10.5 NEUROBIOLOGY 128
10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASE TREATMENT TO DRIVE MARKET 128
TABLE 108 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 109 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 110 EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 111 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 112 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
10.6 CARDIOVASCULAR DISEASES 130
10.6.1 GROWING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET 130
TABLE 113 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 114 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 115 EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 116 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 117 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 133
10.7 OTHER INDICATIONS 133
TABLE 118 CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 119 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 120 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 121 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 122 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
11 CUSTOM ANTIBODY MARKET, BY END USER 136
11.1 INTRODUCTION 137
TABLE 123 CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 137
TABLE 124 CUSTOM ANTIBODY MARKET, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 125 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 126 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 127 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 128 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 139
11.2.1 RISING NEED FOR ANTIBODIES IN BIOMARKER QUANTIFICATION TO DRIVE MARKET 139
TABLE 129 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 130 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 131 EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 132 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 133 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 142
11.3 ACADEMIC & RESEARCH INSTITUTES 142
11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS AND RISING GOVERNMENT-FUNDED INITIATIVES TO DRIVE MARKET 142
TABLE 134 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 135 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 136 EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 137 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 138 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 145
11.4 CONTRACT RESEARCH ORGANIZATIONS 145
11.4.1 ABILITY TO PROVIDE SPECIALIZED SERVICES FOR PRODUCTION OF MABS & ADCS TO SUPPORT MARKET GROWTH 145
TABLE 139 CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 140 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 141 EUROPE: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 142 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 143 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 148
12 CUSTOM ANTIBODY MARKET, BY REGION 149
12.1 INTRODUCTION 150
TABLE 144 CUSTOM ANTIBODY MARKET, BY REGION, 2021–2028 (USD MILLION) 150
12.2 NORTH AMERICA 151
FIGURE 26 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT 152
TABLE 145 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 146 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 153
TABLE 147 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 148 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 149 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 154
TABLE 150 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 154
TABLE 151 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 152 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 155
12.2.1 US 155
12.2.1.1 Rising research in structure-based drug design and therapeutic mAbs to drive market 155
TABLE 153 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 156
TABLE 154 US: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 155 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 156 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 157
TABLE 157 US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 158 US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 158
TABLE 159 US: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 158
12.2.2 CANADA 158
12.2.2.1 Increasing genomic research to fuel market uptake 158
TABLE 160 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 159
TABLE 161 CANADA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 162 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 163 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 160
TABLE 164 CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 165 CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 161
TABLE 166 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 161
12.2.3 NORTH AMERICA: RECESSION IMPACT 162
12.3 EUROPE 162
TABLE 167 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 168 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 163
TABLE 169 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 170 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 171 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 164
TABLE 172 EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164
TABLE 173 EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 165
TABLE 174 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 165
12.3.1 GERMANY 165
12.3.1.1 High investments in development of ADCs to drive market 165
TABLE 175 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 166
TABLE 176 GERMANY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 177 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 178 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 167
TABLE 179 GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 167
TABLE 180 GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 167
TABLE 181 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 168
12.3.2 UK 168
12.3.2.1 Rising pharmaceutical spending and growing life sciences industry to drive market 168
TABLE 182 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 169
TABLE 183 UK: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 184 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 185 UK: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 170
TABLE 186 UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 187 UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 170
TABLE 188 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 171
12.3.3 FRANCE 171
12.3.3.1 Growing pipeline of therapeutic mAbs coupled with rising research investments to support market growth 171
TABLE 189 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 172
TABLE 190 FRANCE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 191 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 192 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 173
TABLE 193 FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 194 FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 173
TABLE 195 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 174
12.3.4 ITALY 174
12.3.4.1 Increasing research activities in proteomics & genomics to drive market 174
TABLE 196 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 175
TABLE 197 ITALY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 198 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 199 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 176
TABLE 200 ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 176
TABLE 201 ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 176
TABLE 202 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 177
12.3.5 SPAIN 177
12.3.5.1 Growing focus on advancements in personalized medicine to support market growth 177
TABLE 203 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 178
TABLE 204 SPAIN: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 205 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 206 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 179
TABLE 207 SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179
TABLE 208 SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 179
TABLE 209 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 180
12.3.6 REST OF EUROPE 180
TABLE 210 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 180
TABLE 211 REST OF EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 212 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 213 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 181
TABLE 214 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182
TABLE 215 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 182
TABLE 216 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 182
12.3.7 EUROPE: RECESSION IMPACT 183

12.4 ASIA PACIFIC 183
FIGURE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT 184
TABLE 217 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 218 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 185
TABLE 219 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 220 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 221 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 186
TABLE 222 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 186
TABLE 223 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 187
TABLE 224 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 187
12.4.1 JAPAN 187
12.4.1.1 Rising research activities for development of ADCs to drive market 187
TABLE 225 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 188
TABLE 226 JAPAN: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 227 JAPAN: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 228 JAPAN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 189
TABLE 229 JAPAN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 190
TABLE 230 JAPAN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 190
TABLE 231 JAPAN: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 190
12.4.2 CHINA 191
12.4.2.1 Increasing establishment of R&D facilities to fuel uptake 191
TABLE 232 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 191
TABLE 233 CHINA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 234 CHINA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 235 CHINA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 192
TABLE 236 CHINA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 193
TABLE 237 CHINA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 193
TABLE 238 CHINA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 193
12.4.3 SOUTH KOREA 194
12.4.3.1 Increasing research on therapeutic antibodies and cytokines to support market growth 194
TABLE 239 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 194
TABLE 240 SOUTH KOREA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 241 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 242 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 195
TABLE 243 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 196
TABLE 244 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 196
TABLE 245 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 196
12.4.4 INDIA 197
12.4.4.1 High pharmaceutical R&D spending to support market growth 197
TABLE 246 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 197
TABLE 247 INDIA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 248 INDIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 249 INDIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 198
TABLE 250 INDIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 199
TABLE 251 INDIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 199
TABLE 252 INDIA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 199
12.4.5 REST OF ASIA PACIFIC 200
TABLE 253 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 200
TABLE 254 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 255 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 256 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 201
TABLE 257 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 201
TABLE 258 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 202
TABLE 259 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 202
12.4.6 ASIA PACIFIC: RECESSION IMPACT 202
12.5 LATIN AMERICA 203
TABLE 260 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 261 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 204
TABLE 262 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 263 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 264 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 205
TABLE 265 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 205
TABLE 266 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 205
TABLE 267 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 206
12.5.1 BRAZIL 206
12.5.1.1 Utilization of therapeutic antibodies for oncology applications to support market growth 206
TABLE 268 BRAZIL: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 207
TABLE 269 BRAZIL: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 270 BRAZIL: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 271 BRAZIL: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 208
TABLE 272 BRAZIL: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 208
TABLE 273 BRAZIL: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 208
TABLE 274 BRAZIL: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 209
12.5.2 REST OF LATIN AMERICA 209
TABLE 275 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 209
TABLE 276 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 277 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 278 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 210
TABLE 279 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211
TABLE 280 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 211
TABLE 281 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 211
12.5.3 LATIN AMERICA: RECESSION IMPACT 212
12.6 MIDDLE EAST & AFRICA 212
12.6.1 INCREASING RESEARCH COLLABORATIONS AND DEVELOPING HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 212
TABLE 282 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021–2028 (USD MILLION) 213
TABLE 283 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 284 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 285 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021–2028 (USD MILLION) 214
TABLE 286 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 214
TABLE 287 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021–2028 (USD MILLION) 214
TABLE 288 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021–2028 (USD MILLION) 215
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 215
13 COMPETITIVE LANDSCAPE 216
13.1 INTRODUCTION 216
13.2 STRATEGIES ADOPTED BY KEY MARKET PLAYERS 216
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 217
FIGURE 28 CUSTOM ANTIBODY MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS 217
13.4 MARKET SHARE ANALYSIS 217
FIGURE 29 CUSTOM ANTIBODY MARKET: MARKET SHARE ANALYSIS OF LEADING PLAYERS (2022) 218
TABLE 289 CUSTOM ANTIBODY MARKET: INTENSITY OF COMPETITIVE RIVALRY 218
13.5 COMPANY EVALUATION QUADRANT 219
13.5.1 STARS 219
13.5.2 EMERGING LEADERS 219
13.5.3 PERVASIVE PLAYERS 220
13.5.4 PARTICIPANTS 220
FIGURE 30 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION QUADRANT 220
13.6 COMPANY EVALUATION QUADRANT FOR STARTUPS (2022) 221
13.6.1 PROGRESSIVE COMPANIES 221
13.6.2 STARTING BLOCKS 221
13.6.3 RESPONSIVE COMPANIES 221
13.6.4 DYNAMIC COMPANIES 221
FIGURE 31 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS (2022) 222
13.7 COMPANY FOOTPRINT 223
13.8 COMPANY SERVICE FOOTPRINT 224
TABLE 290 CUSTOM ANTIBODY MARKET: SERVICE PORTFOLIO ANALYSIS (2022) 224
13.9 COMPANY GEOGRAPHIC FOOTPRINT 225
TABLE 291 CUSTOM ANTIBODY MARKET: GEOGRAPHIC REVENUE MIX (2022) 225
13.10 KEY STRATEGIES ADOPTED BY MARKET PLAYERS 226
13.10.1 CUSTOM ANTIBODY MARKET: KEY DEALS (JANUARY 2020 TO JANUARY 2023) 226
13.10.2 CUSTOM ANTIBODY MARKET: KEY EXPANSIONS (JANUARY 2020 TO JANUARY 2023) 227
14 COMPANY PROFILES 228
(Business overview, Services offered, Recent developments, Other developments & MnM View)*
14.1 KEY MARKET PLAYERS 228
14.1.1 THERMO FISHER SCIENTIFIC, INC. 228
TABLE 292 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 228
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 229
TABLE 293 THERMO FISHER SCIENTIFIC, INC.: DEALS 230
14.1.2 GENSCRIPT 232
TABLE 294 GENSCRIPT: BUSINESS OVERVIEW 232
FIGURE 33 GENSCRIPT: COMPANY SNAPSHOT (2021) 233
TABLE 295 GENSCRIPT: DEALS 234
14.1.3 ABCAM PLC. 236
TABLE 296 ABCAM PLC.: BUSINESS OVERVIEW 236
FIGURE 34 ABCAM PLC.: COMPANY SNAPSHOT (2021) 237
TABLE 297 ABCAM PLC.: DEALS 238
14.1.4 CELL SIGNALING TECHNOLOGY, INC. 240
TABLE 298 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW 240
14.1.5 BIO-RAD LABORATORIES, INC. 242
TABLE 299 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 242
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 243
14.1.6 MERCK KGAA 244
TABLE 300 MERCK KGAA.: BUSINESS OVERVIEW 244
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2021) 245
TABLE 301 MERCK KGAA: DEALS 246
14.1.7 AGILENT TECHNOLOGIES, INC. 248
TABLE 302 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 248
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 249
14.1.8 PERKINELMER, INC. 251
TABLE 303 PERKINELMER, INC.: BUSINESS OVERVIEW 251
FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021) 252
14.1.9 ROCKLAND IMMUNOCHEMICALS, INC. 253
TABLE 304 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW 253
TABLE 305 ROCKLAND IMMUNOCHEMICALS, INC.: DEALS 254
14.1.10 PROMAB BIOTECHNOLOGIES, INC. 255
TABLE 306 PROMAB BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW 255
14.1.11 INNOVAGEN AB 256
TABLE 307 INNOVAGEN AB: BUSINESS OVERVIEW 256
14.1.12 ORIGENE TECHNOLOGIES INC. 257
TABLE 308 ORIGENE TECHNOLOGIES INC.: BUSINESS OVERVIEW 257
14.1.13 BIO-TECHNE 258
TABLE 309 BIO-TECHNE: BUSINESS OVERVIEW 258
FIGURE 39 BIO-TECHNE: COMPANY SNAPSHOT (2021) 259
TABLE 310 BIO-TECHNE: DEALS 260
14.1.14 CREATIVE DIAGNOSTICS 261
TABLE 311 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW 261
14.1.15 SINO BIOLOGICAL, INC. 262
TABLE 312 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW 262
FIGURE 40 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT (2021) 263
*Details on Business overview, Services offered, Recent developments, Other developments & MnM View might not be captured in case of unlisted companies.
14.2 OTHER PLAYERS 265
14.2.1 RAYBIOTECH LIFE, INC. 265
14.2.2 ABBIOTEC, INC. 265
14.2.3 PROSCI INCORPORATED 266
14.2.4 BOSTER BIOLOGICAL TECHNOLOGY 266
14.2.5 CUSABIO TECHNOLOGY LLC 267
14.2.6 BIOINTRON 267
14.2.7 KANEKA EUROGENTEC S.A. 268
14.2.8 CREATIVE BIOLABS 268
14.2.9 ENVIGO 269
14.2.10 IMGENEX INDIA 269
15 APPENDIX 270
15.1 DISCUSSION GUIDE 270
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 274
15.3 CUSTOMIZATION OPTIONS 276
15.4 RELATED REPORTS 276
15.5 AUTHOR DETAILS 277

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • カスタム抗体の世界市場2023～2031：サービス別、抗体種類別、ソース別、研究別、エンドユーザー別、地域別
  • 細胞ベースアッセイの世界市場予測（～2028）：製品＆サービス別、用途別、エンドユーザー別、地域別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(BT6817-23 )"カスタム抗体の世界市場予測（～2028）：サービス別、種類別、ソース別、用途別、疾患別、エンドユーザー別" (英文：Custom Antibody Market by Service (Development, Purification, Labelling), Type (Monoclonal, Recombinant), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology), End User (Biopharma, CROs) - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。